Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter could improve treatment for autoimmune diseases

NCT ID NCT06382675

Disease control Sponsor: Fresenius Medical Care Deutschland GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the filter works well in everyday hospital practice. The goal is to see if the filter can complete the planned treatment in most cases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Plasma Filter PX2 (a device used in therapeutic plasma exchange)
What this could lead to
If successful, this could provide a new, effective option for filtering harmful substances from the blood in people with autoimmune diseases.
What could go wrong
This is a small, early-stage study with no comparison group, so results may not apply to everyone. The filter might not work as well as expected in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent signed and dated by study patient and investigator/authorized physician * Minimum age of 18 years * Patients with an indication for a therapeutical plasma exchange * Patients to be treated with the plasma filter PX2 in combination with the multiFiltrate or multiFiltratePRO * No contraindication against systemic anticoagulation * Ability to understand the nature and requirements of the study Exclusion Criteria: * Patients with known or suspected hypersensitivity to any of the materials of the PX2 plasma filter (Polysulfone, Polyvinylpyrrolidone, Polypropylene, Polyurethane, Silicone) and trial related products * Patients suffering from a heparin allergy * Patients with a prescription for TPE treatment with the completion of \< 0.8 PV and \> 2.0 PV * Any conditions which could interfere with the patient's ability to comply with the study * Women of childbearing age (\< 55 years) without effective means of contraception, pregnancy (pregnancy test will be conducted at start) or lactation period * Participation in a different interventional clinical study during the preceding 30 days * Previous participation in this investigation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité-Universitätsmedizin Berlin

    RECRUITING

    Berlin, State of Berlin, 13353, Germany

  • Klinikum Aschaffenburg-Alzenau

    RECRUITING

    Aschaffenburg, Bavaria, 63739, Germany

  • Klinikum der Ludwig-Maximilians-Universität München (LMU Klinikum)

    RECRUITING

    Munich, Bavaria, 81377, Germany

  • St. Vincenz Kliniken

    RECRUITING

    Paderborn, North Rhine-Westphalia, 33098, Germany

  • Städtisches Klinikum Braunschweig

    RECRUITING

    Braunschweig, Lower Saxony, 38126, Germany

  • Universitätsklinikum Ulm

    RECRUITING

    Ulm, 89081, Germany

  • Universitätsklinikum Würzburg

    RECRUITING

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.